Lendlease offloads infrastructure investor to Japanese buyer
Property giant Lendlease has revealed it’s selling its interest in Capella Capital, a name behind major infrastructure projects such as Melbourne Metro tunnel, to the Sojitz Corporation.
Property giant Lendlease has revealed it’s selling its interest in Capella Capital, a name behind major infrastructure projects such as Melbourne Metro tunnel, to the Sojitz Corporation.
More than four million Bupa customers can continue to use Healthscope hospitals with no gap fee after the companies ended a months-long stand off. But others aren’t so lucky.
ResMed’s competitors might be hamstrung by potential tariffs imposed by the US, boss Mick Farrell says, but adds the company, which delivered a strong quarterly, doesn’t need the help.
Silicon Valley owes its longevity to its ability to pivot and China’s new AI start-up could set it moving in a new direction.
The challenges faced by the electricity grid have been thrown into sharp relief as record solar output fails to offset coal outages and a lack of interconnection, driving spot prices higher.
Australian winemakers are sitting on a glut of mainly red but the reopening of the post-tariff Chinese market has helped ease the pressure by lifting exports 34 per cent in 2024.
There’s no reason Chemist Warehouse’s strong growth won’t continue, the Sigma Healthcare chair says, as the $34bn merger of the two companies passes a crucial vote.
Investors in a luxury tower at Queens Wharf have been refunded millions of dollars in deposits, with interest, after the developer confirmed the project faces three-year delays.
Australian retail supremo Solomon Lew had a first-hand view of how the now two-time US President tackled business deals and it offers plenty of lessons for leaders.
The regulator’s blockbuster action against the casino’s former directors is about to start. And the stakes couldn’t be higher.
After years of trailing Victoria and Queensland, the NSW build-to-rent investment market is taking off, a report by Knight Frank’s Australia says.
The retailer has reported rampaging sales figures, just a day before Sigma Healthcare shareholders are due to vote on a multi-billion dollar merger with the pharmacy retailer.
Activist investor Jeremy Raper has written to the EML Payments board arguing that the company’s brand is beyond repair and it should kick off a sales process.
There’s a grab bag of Australian-listed drug developers that should be on investors’ radars this year, analysts say, with a hefty upside potentially on the cards.
Original URL: https://www.dailytelegraph.com.au/business/victoria-business